NorthStar Medical Radioisotopes and Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, have signed a letter of intent for the commercial supply of copper-67 as an active pharmaceutical ingredient for Clarity’s pipeline of copper-based radiopharmaceuticals, the company announced today.

“With Clarity Pharmaceuticals’ leading copper chelating technology and product pipeline advancing into a range of theranostic clinical trials that use Cu-64/Cu-67 pairing, industrialization of Cu-67 production is required,” NorthStar Medical Radioisotopes CEO Stephen Merrick said in a statement.

According to a release, NorthStar will provide Clarity Pharmaceuticals with Cu-67 as a targeted radiopharmaceutical for the treatment of a range of cancers. Cu-67 is a short-range, beta-emitting radioisotope that is attractive for medical purposes due to its ability to carry sufficient radiation energy to cause cell death in targeted cells.